About TriviumVet
Pets have become family members. This is clear when you browse any social media channel and see countless photos and videos of pets living happily with the people who love them. Sadly, those lives can be interrupted, often devastatingly, by serious diseases. And for many of those diseases, there is either no available therapy or the current therapeutic choices are not ideal.
Pet owners are not satisfied with this situation, and neither are we at TriviumVet. So, we are working with some of the leading veterinarians and therapeutic area specialists around the world to address the gaps in disease management by developing innovative new therapeutic solutions for some of the most serious and underserved conditions. Our efforts are focused on finding effective treatments for unmet needs in Cardiology, Renal Health, Pain Management, Gastroenterology, Wellness Testing, and Age-related Diseases.
OUR WHY: To Bridge The Treatment Gaps In Veterinary Healthcare For Our Pets
OUR MISSION is to deliver innovative healthcare solutions for cats and dogs
OUR VISION as a company is to have a valuable impact on global pet healthcare
Our Work Is Personal For Everyone At TriviumVet
Working to advance the possibilities in the treatment of serious diseases that affect our pets is not just a job for the TriviumVet team, it is a deeply personal calling. Some of us have experienced first-hand the trauma of a pet suffering from a disease for which there was no effective treatment. All of us wish to change the situation so that pet owners can experience the relief of knowing that, should a beloved pet be afflicted by a serious illness, there’s hope that something can be done about it.

Cardiology
Cardiac ailments in dogs and cats are often complex, chronic, and difficult to treat. We are working with some of the most esteemed researchers and academic experts in the field of veterinary cardiology to discover new cardiology solutions for dogs and cats. Our lead cardiology product felycin®-CA1 is the first ever conditionally approved drug for cats with heart disease. Results of the RapaCat study have shown that felycin®-CA1 reduces left ventricular wall thickness in cats with subclinical hypertrophic cardiomyopathy (HCM).

Products:
Felycin®-CA1 (sirolimus delayed release tablets), administered once weekly, is indicated for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).

Pain Management
The veterinary field has an inherent challenge in the assessment of pain (and pain management) because our animals cannot communicate to us verbally about the pain they are experiencing. The TriviumVet team is developing both pharmaceutical pain management solutions and pain assessment tools to measure effectiveness of treatment. These parallel activities represent major advancements in the ability to objectively assess patients with pain and other clinical signs attributed to chronic pain, manage pain more effectively, and understand how well a pain management solution works.

Products:
Liavium-CA1 (pregabalin chewable tablets) - Analgesic for oral use in dogs only.
Indicated for the control of pain and clinical signs associated with Chiari-Like Malformation and Syringomyelia in dogs.
Take Part In Our Clinical Studies
TriviumVet is dedicated to raising the standard of treatment for some of the most serious medical conditions in pets. This requires quality clinical research, and for that we need your help. There are several different ways you can be part of our research driving therapeutic advances to enhance the lives of pets and the people who love them.
Having a pet with a serious health problem is frightening. Participating in a study that is investigating a promising new therapy can not only provide hope for your pet, but it may also allow you and your pet to be part of research that brings hope to many more pets and owners.
News
Irish veterinary pharmaceutical company achieves landmark regulatory milestone for a condition affecting hundreds of thousands of dogs worldwide, with full approval study now being advanced



